“…Indeed, numerous studies suggested that severe amnesia could be observed in patients with non-AD or mixed AD pathology, such as DLB (Kraybill et al, 2005;Yoshizawa et al, 2013;Salmon et al, 2015), FTLD (Elgren et al, 1993;Grahan et al, 2005;, or to a lesser degree VaD (Jicha et al, 2006;Reed et al, 2007). This last decade, memory impairment was reported in clinicallydefined DLB (Petrova et al, 2015;Molano et al, 2010), in the clinical subtypes of FTLD such as behavioural variant frontotemporal dementia (Hornberger et al, 2010;Bertoux et al, 2014), semantic progressive aphasia (Casaletto et al, 2017), non-fluent progressive aphasia (Ramanan et al, 2016), amyotrophic lateral sclerosis (Mantovan et al, 2003), progressive supranuclear palsy (Kobylecki et al, 2015) as well as in clinically-defined VaD (Mathias & Burke, 2009) although inconsistent findings were reported in this disease due to the variable topography of vascular lesions. Not least of all, severe amnesia is also the main feature of hippocampal sclerosis, often related to aberrant TDP-43 immunohistochemistry (Nelson et al, 2019).…”